Loading...

Mani

DB:MJJ
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MJJ
DB
¥252B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Mani, Inc. engages in the research, development, manufacture, and distribution of medical devices and dental instruments in Japan and internationally. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
MJJ Share Price and Events
7 Day Returns
-4%
DB:MJJ
2.2%
DE Medical Equipment
-0.7%
DE Market
1 Year Returns
-
DB:MJJ
6.2%
DE Medical Equipment
-7.6%
DE Market
MJJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mani (MJJ) -4% 8.9% 23.3% - 256.9% -
DE Medical Equipment 2.2% -1.6% 3.2% 6.2% 112.8% 263.8%
DE Market -0.7% -0.8% -3.8% -7.6% 8.2% 11.1%
1 Year Return vs Industry and Market
  • No trading data on MJJ.
  • No trading data on MJJ.
Price Volatility
MJJ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Mani's competitors could be found in our database.

Value

 Is Mani undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mani to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mani.

DB:MJJ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MJJ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.87 (1 + (1- 30.86%) (0%))
0.913
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.913 * 5.96%)
5.67%

Discounted Cash Flow Calculation for DB:MJJ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mani is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MJJ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 5.67%)
2020 4,715.67 Analyst x3 4,462.75
2021 5,734.00 Analyst x3 5,135.43
2022 7,023.00 Analyst x2 5,952.53
2023 8,203.00 Analyst x2 6,579.78
2024 9,099.22 Est @ 10.93% 6,907.20
2025 9,801.33 Est @ 7.72% 7,041.14
2026 10,337.44 Est @ 5.47% 7,027.98
2027 10,740.31 Est @ 3.9% 6,910.26
2028 11,040.66 Est @ 2.8% 6,722.52
2029 11,264.34 Est @ 2.03% 6,490.86
Present value of next 10 years cash flows ¥63,230.46
DB:MJJ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ¥11,264.34 × (1 + 0.23%) ÷ (5.67% – 0.23%)
¥207,566.33
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥207,566.33 ÷ (1 + 5.67%)10
¥119,606.14
DB:MJJ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥63,230.46 + ¥119,606.14
¥182,836.60
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥182,836.60 / 32.81
¥5572.77
DB:MJJ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:MJJ represents 0.00814x of TSE:7730
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00814x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 5,572.77 x 0.00814
€45.34
Value per share (EUR) From above. €45.34
Current discount Discount to share price of €62.40
= -1 x (€62.40 - €45.34) / €45.34
-37.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Mani is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mani's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mani's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MJJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in JPY ¥187.64
TSE:7730 Share Price ** TSE (2019-07-22) in JPY ¥7670
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 31.82x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.75x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mani.

DB:MJJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:7730 Share Price ÷ EPS (both in JPY)

= 7670 ÷ 187.64

40.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mani is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Mani is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Mani's expected growth come at a high price?
Raw Data
DB:MJJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 40.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
2.1%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.49x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:MJJ PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 40.88x ÷ 2.1%

19.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mani is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Mani's assets?
Raw Data
DB:MJJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in JPY ¥1,061.97
TSE:7730 Share Price * TSE (2019-07-22) in JPY ¥7670
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.12x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.71x
DB:MJJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:7730 Share Price ÷ Book Value per Share (both in JPY)

= 7670 ÷ 1,061.97

7.22x

* Primary Listing of Mani.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mani is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Mani's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Mani has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mani expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mani expected to grow at an attractive rate?
  • Mani's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mani's earnings growth is positive but not above the Germany market average.
  • Mani's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MJJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MJJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 2.1%
DB:MJJ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 7.6%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MJJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MJJ Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-08-31 25,400 7,453 1
2022-08-31 23,649 6,655 1
2021-08-31 22,376 6,831 5,753 5
2020-08-31 20,595 5,966 5,072 5
2019-08-31 18,850 8,805 6,297 5
DB:MJJ Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-05-31 18,914 6,156
2019-02-28 19,527 5,490 6,126
2018-11-30 20,195 6,013
2018-08-31 20,102 5,569 3,770
2018-05-31 19,741 3,577
2018-02-28 18,625 4,407 3,298
2017-11-30 17,839 3,316
2017-08-31 17,167 4,793 3,315
2017-05-31 16,815 3,163
2017-02-28 16,942 4,432 3,467
2016-11-30 16,586 3,284
2016-08-31 16,555 3,567 3,005

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mani's earnings are expected to grow by 2.1% yearly, however this is not considered high growth (20% yearly).
  • Mani's revenue is expected to grow by 7.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MJJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Mani Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MJJ Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-08-31
2022-08-31
2021-08-31 172.74 195.10 151.50 5.00
2020-08-31 152.28 161.90 134.70 5.00
2019-08-31 189.00 203.40 171.20 5.00
DB:MJJ Past Financials Data
Date (Data in JPY Millions) EPS *
2019-05-31 187.64
2019-02-28 186.72
2018-11-30 183.27
2018-08-31 114.91
2018-05-31 109.02
2018-02-28 100.52
2017-11-30 101.07
2017-08-31 101.04
2017-05-31 96.41
2017-02-28 105.55
2016-11-30 99.75
2016-08-31 91.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Mani is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Mani's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mani has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mani performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mani's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mani's year on year earnings growth rate has been positive over the past 5 years.
  • Mani's 1-year earnings growth exceeds its 5-year average (72.1% vs 16.6%)
  • Mani's earnings growth has exceeded the DE Medical Equipment industry average in the past year (72.1% vs -0.2%).
Earnings and Revenue History
Mani's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mani Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MJJ Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 18,914.00 6,156.00 4,282.00 1,614.00
2019-02-28 19,527.00 6,126.00 4,593.00 1,614.00
2018-11-30 20,195.00 6,013.00 4,945.00 1,614.00
2018-08-31 20,102.00 3,770.00 4,995.00 1,614.00
2018-05-31 19,741.00 3,577.00 5,238.00 1,221.00
2018-02-28 18,625.00 3,298.00 4,837.00 1,221.00
2017-11-30 17,839.00 3,316.00 4,522.00 1,221.00
2017-08-31 17,167.00 3,315.00 4,260.00 1,221.00
2017-05-31 16,815.00 3,163.00 4,054.00 1,278.00
2017-02-28 16,942.00 3,467.00 3,919.00 1,278.00
2016-11-30 16,586.00 3,284.00 3,967.00 1,278.00
2016-08-31 16,555.00 3,005.00 3,986.00 1,278.00
2016-05-31 16,488.00 3,044.00 4,158.00 1,212.00
2016-02-29 15,520.00 2,830.00 3,760.00 1,212.00
2015-11-30 14,944.00 2,800.00 3,243.00 1,212.00
2015-08-31 13,833.00 2,932.00 2,766.00 1,212.00
2015-05-31 12,489.00 2,831.00 2,403.00 1,061.00
2015-02-28 12,097.00 2,655.00 2,382.00 1,061.00
2014-11-30 11,641.00 2,714.00 2,289.00 1,061.00
2014-08-31 11,440.00 2,606.00 2,162.00 1,061.00
2014-05-31 11,131.00 2,635.00 2,196.00 801.00
2014-02-28 10,486.00 2,499.00 1,993.00 801.00
2013-11-30 9,967.00 2,341.00 1,853.00 801.00
2013-08-31 9,342.00 2,180.00 1,774.00 801.00
2013-05-31 9,216.00 2,057.00 1,642.00 882.00
2013-02-28 9,269.00 2,004.00 1,668.00 882.00
2012-11-30 9,408.00 2,031.00 1,695.00 882.00
2012-08-31 9,693.00 2,179.00 1,646.00 882.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Mani has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Mani used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Mani has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Mani's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mani has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mani's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mani's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mani is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mani's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mani's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Mani has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mani Company Filings, last reported 1 month ago.

DB:MJJ Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 34,842.00 0.00 16,116.00
2019-02-28 34,740.00 0.00 16,005.00
2018-11-30 34,074.00 0.00 14,963.00
2018-08-31 33,546.00 0.00 12,065.00
2018-05-31 32,660.00 0.00 8,880.00
2018-02-28 32,497.00 0.00 8,582.00
2017-11-30 31,429.00 0.00 7,615.00
2017-08-31 30,478.00 0.00 7,468.00
2017-05-31 29,238.00 0.00 6,540.00
2017-02-28 29,219.00 0.00 6,289.00
2016-11-30 27,006.00 0.00 5,848.00
2016-08-31 26,780.00 0.00 5,805.00
2016-05-31 27,359.00 0.00 5,055.00
2016-02-29 27,775.00 0.00 5,769.00
2015-11-30 27,313.00 0.00 6,156.00
2015-08-31 27,334.00 0.00 6,453.00
2015-05-31 26,108.00 0.00 6,081.00
2015-02-28 25,614.00 0.00 8,639.00
2014-11-30 24,182.00 0.00 8,160.00
2014-08-31 23,370.00 0.00 8,354.00
2014-05-31 22,643.00 0.00 7,684.00
2014-02-28 22,394.00 0.00 7,398.00
2013-11-30 21,146.00 0.00 7,545.00
2013-08-31 20,862.00 0.00 7,317.00
2013-05-31 20,194.00 0.00 7,007.00
2013-02-28 19,872.00 0.00 7,489.00
2012-11-30 19,074.00 0.00 7,482.00
2012-08-31 19,148.00 0.00 7,937.00
  • Mani has no debt.
  • Mani has not taken on any debt in the past 5 years.
  • Mani has no debt, it does not need to be covered by operating cash flow.
  • Mani has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Mani's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mani has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mani's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.6%
Current annual income from Mani dividends. Estimated to be 0.8% next year.
If you bought €2,000 of Mani shares you are expected to receive €12 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Mani's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.48%).
  • Mani's dividend is below the markets top 25% of dividend payers in Germany (3.92%).
Upcoming dividend payment

Purchase Mani before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MJJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MJJ Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2023-08-31
2022-08-31
2021-08-31 64.20 5.00
2020-08-31 58.80 5.00
2019-08-31 62.00 5.00
DB:MJJ Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-07-12 46.000 0.590
2019-04-12 46.000 0.679
2019-04-05 46.000 0.788
2019-01-11 46.000 0.904
2019-01-10 46.000 1.017
2018-11-26 46.000 0.980
2018-10-11 46.000 0.913
2018-07-13 40.000 0.807
2018-07-05 40.000 0.821
2018-04-13 40.000 0.822
2018-04-06 40.000 0.939
2017-11-24 38.000 1.027
2017-10-10 38.000 1.202
2017-07-14 34.000 1.291
2017-07-06 34.000 1.241
2017-04-14 34.000 1.141
2017-04-06 34.000 1.349
2016-11-28 34.000 1.268
2016-10-07 34.000 1.416
2016-07-15 30.000 1.422
2016-07-08 30.000 1.538
2015-11-26 30.000 1.620
2015-10-08 30.000 1.340
2015-07-14 26.000 0.985
2015-07-08 26.000 0.958
2015-04-14 26.000 0.967
2015-04-08 26.000 0.883
2015-01-07 26.000 1.053
2014-11-25 26.000 1.104
2014-10-08 26.000 1.179
2014-07-14 20.667 1.038
2014-07-08 20.667 1.082
2014-04-11 20.667 1.286
2014-04-08 20.667 1.424
2013-11-25 20.667 1.631
2013-10-08 20.667 1.686
2013-07-12 20.667 1.777
2013-07-05 20.667 1.711
2013-04-12 20.667 1.838
2013-04-05 20.667 1.884
2012-11-29 20.667 1.899
2012-10-09 20.667 2.039
2012-07-13 20.667 2.258
2012-07-06 20.667 2.285
2012-04-13 20.667 2.245
2012-04-06 20.667 2.133
2012-01-10 20.667 2.261
2011-11-25 20.667 2.361
2011-10-11 20.667 2.282
2011-07-15 20.000 2.209
2011-07-08 20.000 2.074
2011-04-19 20.000 2.138
2011-04-15 20.000 2.094
2011-01-07 20.000 2.027
2010-11-25 20.000 1.952
2010-10-08 20.000 1.961
2010-07-15 20.000 2.026
2010-04-14 20.000 1.855
2010-01-08 16.667 1.524
2009-11-25 16.667 1.739
2009-10-09 16.667 1.603
2009-07-13 13.333 1.259
2009-07-06 16.667 1.604
2009-04-13 13.333 1.418
2008-11-27 11.667 1.329

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mani is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Mani is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Mani's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Mani's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mani's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mani afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mani has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mani's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Toshihide Takai
AGE 67
CEO Bio

Mr. Toshihide Takai has been Chief Executive Officer, Representative Executive President and Chief Operating Officer at Mani, Inc. since November 2013 and served as its Managing Director. Mr. Takai has been Executive Vice-President of Mani, Inc. since November 2011. Toshihide Takai has been President of Mani Resources Co. Ltd. since April 2011. He served as Chief Financial Officer and Representative Executive Officer at Mani, Inc. He served as Advisor of Mani, Inc. Oct 2006 and served as its Corporate Vice President; Manager, Management Planning Department in November 2006, Corporate Vice President in November 2007 and Corporate Executive Vice President in November 2008. Mr. Takai joined Nihon Fudosan Ginko (formerly The Nippon Credit Bank, Limited, now, Aozora Bank, Ltd.) in April 1977 and served as its Investigator of London Branch in September 1984, Manager of New York Branch in September 1997, Manager of Planning Department in January 2000 and Manager of Investment Bank Department in November 2000. He served as Managing Director of Aozora Loan Services Co., Ltd., attached to Personnel Department since June 2001. He served as the Chairman of the Board of Directors at Mani Resources Co., Ltd. since March 2010. He has been Director of Mani, Inc. since November 2013. Mr. Takai has been Director of Mani Hanoi Co., Ltd. since August 2011, Mani Vientiane Co. Ltd. since August 2009, Mani Yangon Ltd. since September 2010, Mani Resources Co. Ltd. since April 2011 and Mani Medical Hanoi Co. Ltd. since March 2010.

CEO Compensation
  • Insufficient data for Toshihide to compare compensation growth.
  • Insufficient data for Toshihide to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Mani management team in years:

4.1
Average Tenure
60.5
Average Age
  • The tenure for the Mani management team is about average.
Management Team

Masaaki Matsutani

TITLE
Executive Chairman
AGE
66

Toshihide Takai

TITLE
MD, President
AGE
67

Kazuo Takahashi

TITLE
Senior VP
AGE
64
TENURE
5.5 yrs

Eiichi Murata

TITLE
Executive Officer
AGE
52
TENURE
2.5 yrs

Toshiyuki Takase

TITLE
Senior VP
AGE
58
TENURE
3.5 yrs

Masahiko Saito

TITLE
Chief Manufacturing Officer
AGE
52
TENURE
4.7 yrs

Kenji Yone

TITLE
Executive Officer
AGE
63
TENURE
2.8 yrs

Teruo Takahashi

TITLE
Executive Officer & Deputy GM of Sales Division
AGE
52
TENURE
4.7 yrs
Board of Directors Tenure

Average tenure and age of the Mani board of directors in years:

5.7
Average Tenure
67
Average Age
  • The tenure for the Mani board of directors is about average.
Board of Directors

Kanji Matsutani

TITLE
Chairman of the Board
COMPENSATION
¥114M
AGE
79
TENURE
14.7 yrs

Masaaki Matsutani

TITLE
Executive Chairman
AGE
66
TENURE
5.7 yrs

Toshihide Takai

TITLE
MD, President
AGE
67
TENURE
5.7 yrs

Kiyoshi Sakai

TITLE
External Director
AGE
74
TENURE
5.7 yrs

Tomoko Masaki

TITLE
External Director
AGE
38
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mani's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mani has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mani, Inc. engages in the research, development, manufacture, and distribution of medical devices and dental instruments in Japan and internationally. It operates through three segments: Surgical Products, Eyeless Products, and Dental Products. The company offers surgical instruments, such as maniplers, maniceps, septum stitches, vessel knives, stainless wire needles, and diamond tomita-saws, as well as stent graft metal skeleton for thoracic aortic aneurysm; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kit. It also provides eyeless and eyed suture needles comprising taper point, cutting, and ophthalmic needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturations, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, stereoscopic microscopes, endodontic accessories, and endodontic micro accessories instruments. In addition, the company imports and sells medical devices. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.

Details
Name: Mani, Inc.
MJJ
Exchange: DB
Founded: 1956
¥2,079,499,921
32,808,925
Website: http://www.mani.co.jp
Address: Mani, Inc.
8-3 Kiyohara Industrial Park,
Utsunomiya,
Tochigi, 321-3231,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 7730 Common Shares The Tokyo Stock Exchange JP JPY 29. Jun 2001
DB MJJ Common Shares Deutsche Boerse AG DE EUR 29. Jun 2001
Number of employees
Current staff
Staff numbers
3,653
Mani employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 20:51
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/07/17
Last earnings filing: 2019/07/12
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.